FreeFree RFPs on Craxy AI — no subscription required

Ready to bid on this RFP?

Sign up free to generate a complete proposal draft instantly — Craxy AI reads the RFP, drafts every section, and matches your past work.

TECHNOLOGY LICENSING OPPORTUNITY: Bacterial Lipid Nanodiscs Platform

Federal · Department of EnergyDue Tuesday, December 15, 2026
Client
Department of Energy
RFP Number
—
Posted
—
Category
US Federal
Budget
—
NAICS
541715
Set-aside
No Set aside used
Contact
Caleb Ledgerwood

Description

AI Generated

The buyer seeks technology licensing for a Bacterial Lipid Nanodiscs Platform. This platform creates uniform nanoscale discs from total lipid extracts harvested from bacterial membranes, encasing the lipid mixture with a membrane scaffold protein to form a stable disc. The platform preserves the full complement of native bacterial lipids in a membranelike environment, enabling accurate evaluation of immunogenic lipids and membrane-associated targets without handling live high-risk pathogens. The technology supports vaccine design and antimicrobial discovery. The buyer has identified antibodies specific to E. coli LPS and Y. pestis membrane lipids using this platform, which are independently licensable.

Official SAM.gov notice

Solicitation number
S-191192
Agency
Department of Energy
Buying office
Triad - DOE Contractor
Notice type
Special Notice
Responses due
Dec 15, 2026, 7:00 PM ET
Posted on SAM.gov
Jun 15, 2026
NAICS
541715 · Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Product/service code
AJ11
Set-aside
No Set aside used
Place of performance
LOS Alamos, NM, 87545
Contracting contact
Caleb Ledgerwood
[email protected]
Additional contact
Lindsay Augustyn
[email protected]
Read the official notice description

The Bacterial Lipid Nanodiscs Platform developed by Los Alamos National Laboratory provides a new way to study entire bacterial membranes in a controlled, nanoscale format derived directly from native lipid extracts. Researchers gain access to membrane components that typically remain difficult to isolate, stabilize or analyze, enabling more accurate evaluation of immunogenic lipids and membrane?associated targets. The platform offers a safer alternative to handling live high?risk pathogens while preserving the biological context that drives meaningful insights for vaccine design and antimicrobial discovery such as therapeutic antibodies to conserved lipids on bacterial membranes. How it Works The Bacterial Lipid Nanodiscs Platform creates uniform nanoscale discs from total lipid extracts harvested from bacterial membranes. Membrane scaffold protein MSP1D1 encases the lipid mixture and forms a stable disc roughly 10 nanometers wide. The resulting particles retain the full complement of native bacterial lipids, arranged in a membrane?like environment that supports realistic biological interactions without requiring synthetic lipids or live cells. Technical Description The method adapts established nanodisc assembly techniques to incorporate entire bacterial lipid extracts rather than defined synthetic lipid mixtures. Total lipids from a pathogen are solubilized, combined with MSP1D1 and dialyzed under controlled conditions to allow the scaffold protein to form a discoidal structure around the heterogeneous lipid population. The process yields nanoparticles that represent the membrane environment of the source organism, including amphiphilic molecules that typically resist purification or structural study when isolated from their native context. The approach was demonstrated using Yersinia pestis, chosen to illustrate how membrane characterization can proceed without the hazards associated with live Tier 1 pathogens. The method captures lipopolysaccharides (LPS) and diverse immunogenic lipids in an arrangement that mirrors their natural organization. Researchers can evaluate binding interactions, immune?stimulating properties and potential antigenic targets in a stable platform that avoids the limitations of outer membrane vesicle purification. Furthermore, using this platform we have identified antibodies specific to E. coli LPS and Y. pestis membrane lipids. These antibodies are independently licensable. Advantages • Provides membrane?like structures using native bacterial lipids • Avoids the safety challenges of handling live pathogens • Offers a broader and more realistic lipid environment than synthetic nanodiscs • Enables improved assessment of membrane antigens and immune responses • Supports analysis of diverse bacterial species using a unified workflow • Creates consistent nanoscale particles suitable for research and development settings Market Applications • Life Sciences Research (membrane biology, immunology) • Vaccine Development (bacterial antigen discovery) • Drug Discovery (membrane?associated targets) • Diagnostics (lipid biomarker exploration) • Biodefense Research (safe pathogen characterization) Development Status: TRL 3 U.S. Patent pending LA-UR-26-24920 LANL Tech Partnerships: Unlock the Innovative Potential Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products. LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact [email protected]. Note: This is not a call for external services for the development of this technology. https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology m.lanl.gov/tech-search

Source: SAM.gov contract opportunities data (U.S. federal public data).

Incumbent

No incumbent history found for this requirement. The notice does not cite a current contract, and no earlier award from this buying office matches it.

Market context

Awards in the same category (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)). This is not this requirement's award history.

Recent similar awards: Department of Energy, NAICS 541715

Vendor and awardValueEnds
SURATECH LLC89243126CSC000213 · MANAGEMENT AND OPERATING CONTRACTOR FOR THE THOMAS JEFFERSON NATIONAL ACCELERATOR FACILITY$304.7MMay 31, 2031
BATTELLE SAVANNAH RIVER ALLIANCE, LLC89303321CEM000080 · SAVANNAH RIVER NATIONAL LABORATORY MANAGEMENT AND OPERATING (M&O) CONTRACT$1.6BFeb 15, 2030
FERMI FORWARD DISCOVERY GROUP, LLC89243024CSC000002 · MANAGEMENT AND OPERATING CONTRACT FOR THE FERMI NATIONAL ACCELERATOR LABORATORY (FNAL)$2.5BDec 31, 2029
GENERAL ATOMICS89233124CNA000365 · RESEARCH & DEVELOPMENT AND FABRICATION OF INERTIAL CONFINEMENT FUSION (ICF) TARGETS FOR TH$92.4MSep 30, 2029
LEIDOS, INC.89243318CFE000003 · RESEARCH SUPPORT SERVICES (RSS)$1.1BDec 30, 2028

Top vendors in this category: Department of Energy, NAICS 541715, since Oct 1, 2023

34 contract awards in this NAICS over the period.

  1. 1. FLUOR MARINE PROPULSION, LLC$5.5B
  2. 2. FERMI FORWARD DISCOVERY GROUP, LLC$2.5B
  3. 3. BATTELLE SAVANNAH RIVER ALLIANCE, LLC$990.2M
  4. 4. LEIDOS, INC.$478.6M
  5. 5. SURATECH LLC$304.7M

Source: USAspending.gov federal award data (U.S. federal public data). A contract is called the incumbent only when the notice or its documents cite it by number.

Source and verification

Original source

Craxy AI summarizes this opportunity from the original listing and available solicitation documents. Confirm submission instructions and amendments with the issuing source before responding.

1 cached source fileDocuments checked

Personalized fit score

Sign up free to see how well this opportunity fits your company — based on your saved profile.

Sign up to see your fit score